Prudent Man Investment Management Inc. Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Prudent Man Investment Management Inc. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 179 shares of the medical research company’s stock, valued at approximately $93,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Edmond DE Rothschild Holding S.A. lifted its position in shares of Thermo Fisher Scientific by 1.0% in the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 36,267 shares of the medical research company’s stock valued at $18,867,000 after acquiring an additional 348 shares in the last quarter. AIA Group Ltd lifted its holdings in shares of Thermo Fisher Scientific by 6.2% in the fourth quarter. AIA Group Ltd now owns 18,764 shares of the medical research company’s stock valued at $9,762,000 after purchasing an additional 1,088 shares in the last quarter. Hazlett Burt & Watson Inc. grew its holdings in shares of Thermo Fisher Scientific by 7.3% during the fourth quarter. Hazlett Burt & Watson Inc. now owns 1,480 shares of the medical research company’s stock valued at $771,000 after buying an additional 101 shares in the last quarter. RWA Wealth Partners LLC raised its position in Thermo Fisher Scientific by 3.5% during the fourth quarter. RWA Wealth Partners LLC now owns 6,903 shares of the medical research company’s stock valued at $3,591,000 after buying an additional 233 shares during the period. Finally, Schroder Investment Management Group boosted its position in Thermo Fisher Scientific by 4.3% during the 4th quarter. Schroder Investment Management Group now owns 1,678,980 shares of the medical research company’s stock worth $873,456,000 after acquiring an additional 69,885 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on TMO shares. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Citigroup lowered their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. UBS Group lifted their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Bank of America dropped their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $653.23.

Thermo Fisher Scientific Stock Down 2.3 %

Shares of TMO stock opened at $499.75 on Monday. The stock has a market cap of $188.53 billion, a P/E ratio of 30.23, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock has a fifty day moving average price of $541.60 and a 200 day moving average price of $551.84. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.34%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.